drugset / Trial / NCT05809752
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Phase 1
Active not recruiting
15 enrolled
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Timeline
- Start
- 2023-08-22
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | 1 cells | Intrathecal |
| Subject | DC vaccine | Vaccine | 2 cells | Intrathecal |
| Subject | DC vaccine | Vaccine | 10 cells | Intrathecal |
| Subject | DC vaccine | Vaccine | 50 cells | Intrathecal |